drugset / Trial / NCT06083454
Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a descriptive, proof of concept, open-label, randomized, 3-arm, window of opportunity trial to evaluate the immunomodulatory role of pharmacological ascorbate with Durvalumab
Timeline
- Start
- 2023-10-23
- Primary completion
- 2025-04-04
- Completion
- 2026-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Vitamin C | Other / unclassified | 75 g | Intravenous |